Received Mar 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 4 | L4EA4 | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 4L454 | — |
Additional vaccination; Additional vaccination; Additional vaccination; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 4-year-old female patient who received HAV (Havrix) (batch number L4EA4, expiry date 22-JAN-2027) for prophylaxis. Co-suspect products included HAV (Havrix) (batch number 4L454, expiry date 16-OCT-2026) for prophylaxis and DTPa-IPV (Kinrix) for prophylaxis. On 06-MAR-2026, the patient received the 4th dose of Havrix. On 05-FEB-2026, the patient received the 3rd dose of Havrix. On 05-MAR-2026, the patient received the 6th dose of Kinrix. On 05-FEB-2026, an unknown time after receiving Havrix, the patient experienced extra dose administered (Verbatim: Additional vaccination). On 05-MAR-2026, the patient experienced extra dose administered (Verbatim: Additional vaccination). On 06-MAR-2026, the patient experienced extra dose administered (Verbatim: Additional vaccination). The outcome of the extra dose administered, extra dose administered and extra dose administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-MAR-2026 The nurse called to get guidance after a 4-year-old patient was vaccinated with repeated doses of Havrix and Kinrix. The nurse wanted to know how to proceed and if there were some safety concerns for the patient. The batch number was not provided upon follow- up with the reporter.